Russia claims 91.4% efficacy rate in new Covid-19 vaccine data

 The Indian Express

December 14, 2020

Reuters

The results are crucial for India, where the vaccine is being tested on humans in mid- to late-stage trials by Hyderabad-based Dr Reddy’s Laboratories.

Russian coronavirus vaccine developers published fresh results from their trial of the Sputnik V vaccine on Monday based on new data, and said the shot had again been found to be 91.4% effective in providing protection from Covid-19. The results are crucial for India, where the vaccine is being tested on humans in mid- to late-stage trials by Hyderabad-based Dr Reddy’s Laboratories.

More than 100,000 people have already been vaccinated against the disease as part of Russia’s mass inoculation programme, which began in September alongside a Moscow-based human trial of the shot. The new results are based on  data from 22,714 participants in the trial, and were published after 78 confirmed coronavirus cases were reported among the group, researchers at the Gamaleya Institute said in a statement made on Monday with the Russian Direct Investment Fund (RDIF), which is marketing the shot abroad Of the 78 cases, 62 occurred among participants who received a placebo, the researchers said, adding that in the trial overall the ratio of those who received the placebo to those who were vaccinated was 1 to 3. Twenty of the infected participants who received a placebo suffered severe symptoms of Covid-19, the statement said.

There were no severe cases of the disease among the 16 vaccinated trial participants, the statement said. “Analysis of the new data found Sputnik V, named after the Soviet-era satellite that triggered the space race, to have a 91.4% efficacy rate,” the statement said. The results, described as a “final control point” in the trial, were identical to interim results published on November 24, based on 39 cases of coronavirus among trial participants, that also found the shot to be 91.4% effective.

“I believe we will be able to vaccinate most of the population in Russia in 2021,” Gamaleya Institute director
Alexander Gintsburg was cited in the statement as saying. The data will be published by the Gamaleya Institute in an international peer-reviewed medical journal, the statement said.

“We will definitely share the results achieved with the scientific community and will be happy to discuss them with all interested colleagues,” Gamaleya Institute’s Denis Logunov was cited as saying.

The results will also be used to submit the shot for emergency-use authorisation in other countries. Trials of
Sputnik V are ongoing in Belarus, the United Arab Emirates and Venezuela.

https://indianexpress.com/article/world/russia-repeats-91-4-efficacy-rate-in-new-covid-19-vaccine-data-7104740/ 

 

Comments

Post a Comment

Popular posts from this blog

India Joins Russia in Voting Against West-Backed Move to Expand Powers of OPCW

The Wire: June 28, 2018 New Delhi: India voted against a UK-backed move that will allow the global chemical weapons watchdog to apportion blame for illegal attacks, criticising the decision to grant “unchecked powers” to the head of the group which could be used for “partisan” purposes. On Wednesday, more than two-thirds of the member states of the Organisation for the Prohibition of Chemical Weapons (OPCW) voted to authorise the international body to identify the perpetrators and sponsors of a chemical weapons attack. It also specifically called on the OPCW’s technical secretariat to begin work on identifying the perpetrators behind the use of chemical weapons in Syria. The draft decision, sponsored by 30 countries, was adopted at the fourth special session of the conference of the states parties to the Chemical Weapons Convention at the Hague, with 82 in favour and 24 negative votes. While Europe, the United States and their allies voted ‘yes’, there was strong oppo...
Read more

As financial insecurity rises in urban India, so does investment in insurance

Image
Scroll.in March 13, 2020 Urban Indians are becoming less confident about their financial security. Up to 58% of them fret over financial independence post retirement, which is a 4% increase from last year. An equal share of urban Indians worry about meeting their daily medical expenses and sustaining their current lifestyle once they stop working. The findings are part of a survey published by Delhi-based Max Life Insurance in association with London-based consultancy Kantar. The firms surveyed 7,014 respondents in 25 cities, including six metros, nine tier-1 cities, and 10 tier-2 cities, between December 2019 and January 2020. Source: Max Life Insurance via Quartz The trends Source: Max Life Insurance via Quartz Source: Max Life Insurance via Quartz Source: Max Life Insurance via Quartz A significant share of urban Indians also say their families will have no financial support in the event of the breadwinner’s death. In such a scenario, around 57% believe the family sav...
Read more

ED tracks Swiss Bank A/Cs of Agusta scamster

The Poineer February 10,2019 Rakesh K Singh The Enforcement Directorate (ED) has tracked a dozen Swiss bank accounts in the name of Rajiv Saxena, who is key accused in the Rs 3,600 crore AgustaWestland VVIP chopper scam. The ED has also found out accounts held by  his family members and associates where the kickbacks in the now scrapped deal were allegedly parked. Two bank accounts are in the name of Rajiv Saxena’s  associates Pankaj Jain and Sumita Jain who are also the authorised signatories. The  third is in the name of another associate Ajit Singh Bubber, but Rajiv and his family members are authorised signatories. The remaining nine accounts are largely owned and operated by Rajiv, his family members and associates. Rajiv Saxena was deported by the UAE authorities on January 30 and the ED formally arrested him the next day and a court later granted his remand to the agency. He is currently undergoing custodial interrogation by the ED. The agency had in 2017...
Read more